Research
Could Early Eosinophilic Esophagitis Treatment Prevent Asthma?
The Brief
- An observational study found that early dupilumab (Dupixent) treatment for eosinophilic esophagitis in young children was associated with a reduced risk of developing asthma.
- The study used data from a large commercial insurance database.
- The findings were reported by MedPage Today from a meeting presentation (ACAAI).
Why it matters
The result is an association from an observational study, so it does not establish that dupilumab prevents asthma, but it suggests a possible link between early treatment of an allergic-type condition and later asthma risk that researchers may test further.
Who’s affected
- clinicians treating children with eosinophilic esophagitis
- allergists and pediatric pulmonologists
- researchers studying allergic disease progression
- #dupilumab
- #eosinophilic esophagitis
- #asthma
- #pediatrics
- #allergy
(MedPage Today) -- Early treatment with dupilumab (Dupixent) for eosinophilic esophagitis in young children was associated with reduced risk of developing asthma, an observational study showed. Among children in a large commercial insurance database...
Timeline
MedPage Today reported the observational study findings on early dupilumab treatment and asthma risk
MedPageToday.com - medical news for physicians
Could Early Eosinophilic Esophagitis Treatment Prevent Asthma?